BrainStorm Cell Therapeutics Wins 2020 ‘Buzz of BIO’ Award for Investigational Cellular Treatment

BrainStorm Cell Therapeutics Wins 2020 ‘Buzz of BIO’ Award for Investigational Cellular Treatment

For its promising investigational therapeutic approach to neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), BrainStorm Cell Therapeutics is the Buzz of BIO 2020 winner in the Public Therapeutic Biotech category.

The Buzz of BIO contest identifies U.S. companies with groundbreaking, early-stage potential to improve lives. The event also is an opportunity to make investor connections that could take products to the next phase.

Ten biotechnology companies are nominated in each of the three categories of Buzz of BIO: Public Therapeutic Biotech, Private Therapeutic Biotech, and Diagnostics and Beyond. In the Public Therapeutic Biotech category that BrainStorm won, nominated companies must be actively developing a publicly traded human treatment intended for review by the U.S. Food and Drug Administration (FDA).

As a developer of autologous cellular therapies — treatments that use a patient’s own cells and tissues — for debilitating neurodegenerative diseases, BrainStorm is now testing its NurOwn therapy for safety and effectiveness. The treatment involves extracting, from human bone, marrow-derived mesenchymal stem cells (MSCs), which are capable of differentiating into other cell types. The MSCs are then matured into a specific cell type that produces neurotrophic factors — compounds that promote nervous tissue growth and survival. They are then reintroduced to the body via injection into muscles and/or the spinal canal.

Backed by a California Institute for Regenerative Medicine grant, Brainstorm has fully enrolled its randomized, double-blind, placebo-controlled Phase 3 clinical trial (NCT03280056) at six U.S. sites in California, Massachusetts, and Minnesota. Some 200 ALS patients are participating. A secondary safety analysis by the trial’s independent Data Safety Monitoring Board (DSMB) revealed no new concerns. Every two months, study subjects will be given three injections into the spinal canal of either NurOwn or placebo.

The trial is expected to conclude late this year. Results will be announced shortly afterward.

In a Phase 2 study (NCT02017912), which included individuals with rapidly progressing ALS, NurOwn demonstrated a positive safety profile as well as prospective efficacy.

The use of autologous MSC cells to potentially treat ALS was given orphan drug status by both the FDA and the European Medicines Agency.

“Thanks to everyone who voted for BrainStorm during the Buzz of BIO competition,” Chaim Lebovits, BrainStorm president and CEO, said in a press release. “The entire management team at BrainStorm was very pleased with the results of this competition, and we look forward to presenting to an audience of accredited investors who may benefit from the company’s story. We thank the BIO [Biotechnology Innovation Organization] team for singling out BrainStorm’s NurOwn as a key technology with the potential to improve lives.”

As a contest winner, BrainStorm is invited to give a presentation at the Bio CEO & Investor Conference, to be held Feb. 10–11 in New York City, along with exposure to multiple industry elites and potential investors.

NurOwn cells also are being tested in a Phase 2 clinical study (NCT03799718) in patients with progressive multiple sclerosis.

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Total Posts: 7
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
×
Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Latest Posts
  • Christmas illumination project, ALS
  • Buzz of BIO
  • REFINE-ALS
  • REFINE-ALS

5 comments

  1. Bill says:

    I greatly applaud Brainstorms efforts. I am also a bit sickened by the outright reality that this Award is all about investors. Some investors will pay a huge sum for the rights. In turn, that investment will have to be repaid, along with likely an outrageous profit margin, by a relatively small number of pALS. I think it will cause insurance companies and Medicare to further delay approval when that time comes.
    Although I do truly applaud the research I am very afraid of the massively jacked up cost we will be faced with. Our government here in US has little interest in helping but currently a great interest in protecting profits of big Pharma.

  2. Karin Laurie says:

    I am also disheartened. No where do I see what is being done to fast track this treatment to existing ALS and other MN disease sufferers… we wait and are dying while the people that will profit only see a financial goal..

  3. PhilipJax says:

    Everyone:
    Learn details about all current and past Stem Cell trials at the website: https://endals.altervista.org/#stem

    For example, on 06Jan2020 AstroRx® reported some favorable results from Cohort A of its 4-cohort stem cell trial. However, the therapy has some drawbacks which are explained.
    In addition there are details on all other available and prospective therapies: Gene Therapy, Immunotherapy, Stem Cell Therapy, Antiviral Therapy, Neuroprotective Agents and Diet and Exercise. Each topic offers links to the latest research reports on the subject.

    Also, in the website’s right column you will find details on many Care Management topics, including Best Insurance, How to Evaluate Clinical Trials, VA Benefits, Group Homes and Scams.
    PhilipJax

Leave a Comment

Your email address will not be published. Required fields are marked *